New drug aims to lock in remission for rare lymphoma
NCT ID NCT07647432
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether the drug elranatamab can help keep plasmablastic lymphoma, a rare and aggressive blood cancer, from returning after initial chemotherapy. About 17 adults with or without HIV who have already responded to first treatment will receive elranatamab injections for up to 6 cycles. The main goals are to see if patients can complete the treatment and whether it improves remission rates.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- elranatamab
- What this could lead to
- If it works, this could point toward a way to keep plasmablastic lymphoma from coming back after initial treatment.
- What could go wrong
- This is a very small, early feasibility study with only 17 participants, so results may not apply broadly. Elranatamab can cause serious side effects like cytokine release syndrome and nerve problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONSOLIDATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Peer support may lift the cloud of loneliness for older gay men with HIV
- Can peer mentors help gay men with HIV stay in care?
- HIV and hidden health risks: a major study probes the link
- Faith-Based therapy aims to heal trauma in young women
- Bringing HIV care to the community: a new test in zambia
- Could intense workouts reverse cognitive decline in older HIV patients?